This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 11068-27-228		FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.				
International application No. PCT/US03/04373		International filing date (day/month/year) 14 February 2003 (14.02.2003)		(Earliest) Priority Date (day/month/year) 15 February 2002 (15.02.2002)			
Applicant VIROLOGIC, INC.							
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This international search report consists of a total of 4 sheets. It is also accompanied by a copy of each prior art document cited in this report.							
Basis of the Report a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).							
searc	 b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. 						
	filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.						
քա							
L fu	furnished subsequently to this Authority in computer readable form.						
	the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.						
	the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.						
2 C	Certain claims were found unsearchable (See Box I).						
	nity of invention is lacki	ng (See Box II).					
l — _	d to the title,						
	the text is approved as submitted by the applicant.						
th	e text has been establishe	d by this Authority to read as follo	ws:				
5. With regard to the abstract,							
∐ և	the text is approved as submitted by the applicant.						
m	the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.						
6. The figure of the drawings to be published with the abstract is Figure No.							
as	suggested by the applica	nt.		None of the figures			
<u> </u> be	cause the applicant failed	d to suggest a figure.					
b	because this figure better characterizes the invention.						

Form PCT/ISA/210 (first sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

CTA		PC 170 S03/0437	<u>. </u>			
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/70 US CL : 435/5						
According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED						
Minimum de	OCTIMENTATION searched (classification quater followed by 1 cm.)	•				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/5, 7.1, 69.1, 91.2, 320.1, 455, 456; 530/389.4						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Shect						
	UMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevan	it passages	Relevant to claim No.			
Y	US 5,837,464 A (CAPON et al.) 17 November 1998 (17.11.1998), column 52, line51.	51, line 40 to	1-7, 11, 12			
A	Column 52, imes 1.	į				
			8-10, 13-16			
Y	AUEWARAKUL et al. Application of HIV-1-green fluorescent protein (GFI	P) reporter	1, 2, 3, 6			
A	viruses in neutralizing antibody assays. Asian Pacific Journal Allergy Immur 2001, Vol. 19, No. 2, pages 139-144, entire document.	nology. June				
		ļ	4, 5, 7-16			
Y	CHO et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutra	lizing	1, 2, 3, 6			
A	antibody response but is unable to provide sterilizing protection against heter Simian/human immunodeficiency virus infection in pigtailed macaques. Jour	cologous	4.6.7.46			
	virology. March 2001, Vol. 75, No. 5, pages 2224-2234, entire document	i i	4, 5, 7-16			
Y	DORSKY et al. Detection of HIV-1 infection with a green fluorescent protein	n reporter	1, 2, 3, 6			
A	system. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology. December 1996, Vol. 13, No. 4, pages 308-313, entire document.					
	1999, 161. 15, 110. 4, pages 300-315, enure document.		4, 5, 7-16			
		j				
j		ĺ				
		1				
	documents are listed in the continuation of Box C. See patent fami	•				
	ecial categories of cited documents: "T" later document pub	lished after the intern	ational filing date or priority on but cited to understand the			
of particula	defining the general state of the art which is not considered to be principle or theory ar relevance	underlying the invent	ion			
	"E" earlier application or patent published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step					
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as "Y" document of particular relevance; the claimed invention cannot be specified)						
"O" document referring to an oral disclosure, use, exhibition or other means being obvious to a person skilled in the art						
P document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed						
Date of the actual completion of the international search Date of mailing of the international search Date of mailing of the international search report						
Na (Na) 2003 (08.03.2003)						
Name and mailing address of the ISA/US Authorized officer						
Mail Stop PCT, Atm: ISA/US Commissioner for Patents Ulfile Winkler						
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. 703-308-0196						
acsimile No. (703)305-3230						
rm PCT/ISA/210 (second sheet) (July 1998)						

PCT/US03/04373

INTERNATIONAL SEARCH REPORT

C. (Contin	C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Y A	MONTEFIORI et al. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. Journal of Virology. November 2001, Vol. 75, No. 21, pages 10200-10207, entire document.	1, 2, 3, 6 			
Y A	HIOE et al. Resting cell neutralization assay for HIV-1 primary isolates. Methods. August 1997, Vol. 12, No. 4, pages 300-305, entire document.	1, 2, 3, 6 			
Α ·	RENCHER et al. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Research and Human Retroviruses. September 1995, Vol. 11, No. 9, pages 1131-1133.	1-16			
	·				
ů,					

INTERNATIONAL SEARCH REPORT	PC1/US03/04373
Continuation of B. FIELDS SEARCHED Item 3: WEST, DERWENT, STN-BIOSIS, MEDLINE, EMBASE inventor search, viral entry, inhibition, fusogenic, neutralizing antibody.	
·	

Form PCT/ISA/210 (second sheet) (July 1998)

NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- (Where originally there were 48 claims and after amendment of some claims there are 51):
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- 2. [Where originally there were 15 clasms and after amendment of all clasms there are 11]: "Clasms 1 to 15 replaced by amended clasms 1 to 11."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if stanslated into English.

It should not be confounded with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and assent be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It should not countil any dispensing comments on the international search report or the relevance of citations contained in the export. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an emendment of that claim.

In what language ?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

Consequence if a demand for international preliminary examination has already been filed?

If, at the time of filing any amendments under Article 19, a donard for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Buress, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase?

The appliment's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.